Tenofovir
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Truvada | — | 2005-02-20 | europa.eu ↗ |
| Approved | US (FDA) | TRUVADA | — | 2004-08-02 | fda.gov ↗ |
Trials 164 · started per year
Also used as a comparator or background therapy in 162 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05523648 Background | Jan 2020 → Dec 2021 | NAFLD1, chronic hepatitis B virus infection | Sichuan Leshan Traditional Chinese Medicine Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02280109 Comparator | Nov 2014 → Dec 2015 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT03706924 Comparator | Jun → Oct 2018 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 1 | NCT02832778 Background | Nov 2016 → Jan 2018 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 1 | NCT02750540 Comparator | Oct 2016 → May 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02797522 Background | Jun → Nov 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02499874 Background | Aug 2015 → Oct 2017 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT02288208 Background | Nov 2014 → May 2015 | chronic hepatitis B virus infection | TetraLogic Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01768962 Comparator | Apr → Dec 2014 | — | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01694407 Comparator | Feb → Dec 2013 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01687205 Comparator | Nov 2012 → Jun 2014 | — | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01283360 Comparator | Oct 2010 → May 2013 | — | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01040091 Comparator | Dec 2009 → Apr 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00667433 Background | Jun 2008 → Dec 2011 | HIV infectious disease | David A Wohl, MD | Completed | No outcome recorded |
| Phase 1 | NCT00365339 Comparator | Apr → Jun 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06295328 Comparator | Apr 2022 → Apr 2025 overdue | chronic hepatitis B virus infection | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05203055 Background | Dec 2021 → Dec 2022 | chronic hepatitis B virus infection | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02475915 Background | Jan → Nov 2015 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT02338674 Comparator | Oct 2014 → Oct 2016 | chronic hepatitis B virus infection | Fuzhou General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01027065 Background | Dec 2009 → Nov 2012 | chronic hepatitis B virus infection | Cytheris SA | Unknown | No outcome recorded |
| Phase 1/2 | NCT02179138 Background | ? → Mar 2015 | — | CONRAD | Withdrawn | No outcome recorded |
| Phase 231 trials | ||||||
| Phase 2 | NCT06799650 Background | Jan → Nov 2025 overdue | post-viral disorder | Federal University of São Paulo | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06676410 Comparator | Jul 2023 → Dec 2024 overdue | HIV infectious disease | Code Pharma | Recruiting | No outcome recorded |
| Phase 2 | NCT05808335 Background | Jan 2022 → Mar 2024 | chronic hepatitis B virus infection | ImmuneMed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04189276 Comparator | Dec 2019 → Jun 2021 | hepatitis B virus infection | Tasly Tianjin Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02751996 Comparator | May 2016 → Feb 2020 | hepatitis B virus infection | F-star Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02888106 Background | Apr 2016 → Nov 2019 | chronic hepatitis B virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02738008 Background | Mar → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02336074 Background | Nov 2015 → Nov 2017 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT02604212 Background | Nov 2015 → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02604199 Background | Sep 2015 → Jan 2017 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02452528 Background | Aug 2015 → Dec 2016 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02391805 Background | May 2015 → Oct 2017 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02750059 Comparator | Jan 2015 → Feb 2018 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02116660 Comparator | Sep 2014 → Jul 2017 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01687218 Comparator | Sep 2013 → May 2015 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 2 | NCT01803074 Background | Apr 2013 → Nov 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01706575 Background | Jan → Sep 2013 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01641809 Background | Aug 2012 → Oct 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01291459 Background | Sep 2011 → Dec 2015 | HIV infectious disease | Association Pour la Recherche en Infectiologie | Unknown | No outcome recorded |
| Phase 2 | NCT01384734 Background | Jul 2011 → Feb 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01338883 Comparator | Jun 2011 → Dec 2012 | HIV infectious disease | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00822315 Background | Jul 2009 → Nov 2011 | HIV infectious disease, tuberculosis | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00932971 Comparator | Jun 2009 → Aug 2017 | hepatitis D virus infection | HepNet Study House, German Liverfoundation | Completed | No outcome recorded |
| Phase 2 | NCT00768989 Comparator | Nov 2008 → Jan 2010 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00654147 Comparator | Apr 2008 → Jan 2012 | HIV infectious disease | Margaret A. Fischl, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01174914 Comparator | Mar 2008 → Mar 2010 | — | The Ojai Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00524173 Comparator | Aug 2007 → Feb 2017 | hepatitis B virus infection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| Phase 2 | NCT00350272 Background | May 2006 → Aug 2007 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00120367 Background | Apr 2005 → Dec 2007 | HIV infectious disease, progressive multifocal leukoencephalopathy | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00100048 Background | Jan 2005 → Oct 2006 | AIDS | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00214890 Comparator | Dec 2004 → Jun 2008 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT04742491 Background | Mar 2021 → Aug 2024 | — | HIV Prevention Trials Network | Completed | No outcome recorded |
| Phase 2/3 | NCT04359095 Comparator | Aug 2020 → Mar 2021 | COVID-19 | National University of Colombia | Completed | No outcome recorded |
| Phase 2/3 | NCT03227731 Comparator | Sep 2017 → Dec 2021 | HIV infectious disease | University of KwaZulu | Completed | No outcome recorded |
| Phase 2/3 | NCT02245022 Comparator | Mar 2017 → Dec 2018 | HIV infectious disease, pregnancy disorder | University of Liverpool | Completed | No outcome recorded |
| Phase 2/3 | NCT02104700 Comparator | Apr 2014 → May 2016 | HIV infectious disease | Philip Grant | Completed | No outcome recorded |
| Phase 2/3 | NCT01154673 Background | Nov 2011 → Sep 2014 | — | University of Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT00946595 Comparator | Nov 2009 → Jul 2013 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2/3 | NCT00476983 Background | — | — | The HIV Netherlands Australia Thailand Research Collaboration | Withdrawn | No outcome recorded |
| Phase 339 trials | ||||||
| Phase 3 | NCT07095855 Background | Aug 2025 → Jan 2028 expected | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05592613 Background | Feb 2023 → Jul 2024 | HIV infectious disease | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05378399 Background | Dec 2022 → Feb 2026 | HIV infectious disease, substance-related disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02650271 Comparator | Feb 2021 → Dec 2023 | hepatocellular carcinoma | Guangxi Medical University | Completed | No outcome recorded |
| Phase 3 | NCT04022967 Comparator | Sep 2020 → Feb 2025 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT04303598 Background | Apr 2020 → May 2022 | HIV infectious disease | Henan Genuine Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03512418 Background | Jun 2019 → Apr 2024 | HIV infectious disease, substance-related disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03759782 Background | Jan 2019 → Jan 2022 | chronic hepatitis B virus infection | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT03256422 Background | Sep 2017 → Aug 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02987530 Background | Apr 2017 → Jul 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02486133 Comparator | Jul 2015 → May 2018 | HIV infectious disease | Technical University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT02403674 Background | Jun 2015 → Mar 2017 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02219672 Comparator | Jul 2014 → Jul 2016 | AIDS | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT02157311 Background | Jul 2014 → Jan 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02369965 Comparator | Feb 2014 → Apr 2018 | AIDS | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01937806 Comparator | Oct 2013 → Feb 2016 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT01910402 Comparator | Aug 2013 → Sep 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT01848743 Comparator | Apr 2013 → Apr 2016 | chronic hepatitis B virus infection | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| Phase 3 | NCT01872988 Comparator | Sep 2012 → Feb 2018 | chronic hepatitis B virus infection, hepatocellular carcinoma | Taichung Veterans General Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT01620944 Comparator | Jul 2012 → Jan 2013 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT01605084 Background | Jun 2012 → Aug 2014 | HIV infectious disease | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 3 | NCT01516970 Background | Nov 2011 → Aug 2013 | HIV infectious disease | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01061151 Comparator | Mar 2011 → Sep 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT01066962 Comparator | Aug 2010 → Oct 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01033760 Background | Apr 2010 → Jul 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00936195 Comparator | Jan 2010 → Jan 2013 | HIV infectious disease, pregnancy disorder | French National Agency for Research on AIDS and Viral Hepatitis | Withdrawn | No outcome recorded |
| Phase 3 | NCT00928187 Comparator | Nov 2009 → Sep 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00808002 Background | Feb 2009 → Nov 2011 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00823342 Comparator | Dec 2008 | chronic hepatitis B virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| Phase 3 | NCT00805675 Comparator | Nov 2008 → Dec 2010 | chronic hepatitis B virus infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00745823 Background | Sep 2008 → Oct 2010 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00410202 Comparator | Mar 2008 → Jan 2011 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00427297 Comparator | Sep 2007 → May 2009 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| Phase 3 | NCT00369941 Background | Aug 2006 → May 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00302822 Background | Apr 2006 → Dec 2009 | AIDS | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT01003990 Comparator | Oct 2002 → Feb 2016 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00044577 Background | Jul 2002 → May 2004 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00035932 Comparator | Nov 2001 → Jul 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 451 trials | ||||||
| Phase 4 | NCT03142256 Comparator | Mar 2017 → Jun 2019 | — | Desmond Tutu HIV Centre | Unknown | No outcome recorded |
| Phase 4 | NCT03084250 Comparator | Mar 2017 → Apr 2023 | hepatitis B virus infection | Shanghai Nanhui Nanhua Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03120494 Background | Nov 2016 → Jun 2019 | AIDS | Puerto Rico Community Network for Clinical Research on AIDS | Unknown | No outcome recorded |
| Phase 4 | NCT02924389 Background | Sep 2016 → Sep 2019 | HIV infectious disease | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT02770508 Comparator | Nov 2015 → Jul 2017 | HIV infectious disease | Fundación Huésped | Completed | No outcome recorded |
| Phase 4 | NCT02529059 Background | Nov 2015 → May 2017 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 4 | NCT02577042 Comparator | Oct 2015 → Jun 2018 | — | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 4 | NCT02547844 Background | Sep 2015 → Oct 2016 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02198443 Comparator | Jun 2015 → Jul 2016 | HIV infectious disease | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 4 | NCT02285374 Background | Nov 2014 → Mar 2015 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 4 | NCT02057796 Background | Sep 2014 → Apr 2018 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 4 | NCT02238860 Comparator | Sep 2014 → Sep 2016 | cirrhosis of liver | Asian Institute Of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01902186 Comparator | Sep 2014 → Dec 2016 | HIV infectious disease | Giovanni Di Perri | Terminated | No outcome recorded |
| Phase 4 | NCT01829802 Comparator | May 2014 → Oct 2017 | HIV infectious disease | Pedro Cahn | Unknown | No outcome recorded |
| Phase 4 | NCT01781806 Comparator | May 2013 → May 2016 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT01711567 Comparator | Apr 2013 → Dec 2015 | chronic hepatitis B virus infection | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT01641367 Background | Feb 2013 → Nov 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT01694017 Comparator | Nov 2012 → Aug 2014 | HIV infectious disease | Tufts University | Completed | No outcome recorded |
| Phase 4 | NCT01639092 Comparator | Sep 2012 → Mar 2018 | chronic hepatitis B virus infection | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01639066 Comparator | Sep 2012 → Sep 2017 | chronic hepatitis B virus infection | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01576731 Background | Jul 2012 → Jul 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01373684 Comparator | May 2012 → Oct 2019 | chronic hepatitis B virus infection | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 4 | NCT01533272 Background | Feb 2012 → Jun 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01380080 Background | Oct 2011 → Jan 2015 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT01274780 Background | May 2011 → May 2013 | — | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT01335620 Background | Apr 2011 → Dec 2012 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT01232127 Background | Feb → Jun 2011 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01258439 Comparator | Nov 2010 → Jul 2014 | HIV infectious disease, cardiovascular disorder | St Vincent's Hospital, Sydney | Completed | No outcome recorded |
| Phase 4 | NCT01173510 Background | Aug 2010 → Oct 2012 | AIDS | Community Research Initiative of New England | Withdrawn | No outcome recorded |
| Phase 4 | NCT01118871 Comparator | May 2010 → May 2013 | HIV infectious disease | Imperial College London | Terminated | No outcome recorded |
| Phase 4 | NCT01102972 Comparator | Apr 2010 → Jun 2012 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT00931801 Comparator | Dec 2009 → Feb 2012 | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Phase 4 | NCT00762892 Comparator | Jan 2009 → Dec 2012 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT00677300 Comparator | Jan 2009 → Oct 2012 | HIV infectious disease | Dallas VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00757783 Background | Oct 2008 → Aug 2009 | HIV infectious disease | Tibotec, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00775606 Comparator | Oct 2008 → Dec 2010 | AIDS | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01601899 Comparator | Oct 2008 → Oct 2010 | metabolic disease | University of Witwatersrand, South Africa | Terminated | No outcome recorded |
| Phase 4 | NCT00759070 Comparator | Sep 2008 → Jul 2013 | HIV infectious disease | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 4 | NCT00662545 Comparator | Apr 2008 → Feb 2010 | HIV infectious disease, hepatitis B virus infection | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00632970 Background | Feb 2008 → Feb 2010 | HIV infectious disease | George Washington University | Terminated | No outcome recorded |
| Phase 4 | NCT01074645 Comparator | Nov 2007 → Jun 2009 | hepatitis B virus infection, liver failure | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00544128 Comparator | Oct 2007 → Feb 2012 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 4 | NCT00532168 Background | Sep 2007 → Dec 2012 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00444379 Comparator | Apr 2007 → Feb 2012 | HIV infectious disease, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00335322 Comparator | Feb 2007 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00192634 Comparator | Dec 2005 → Aug 2008 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00244712 Comparator | Jul 2005 → Apr 2008 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00344760 Background | Jan 2005 → Mar 2007 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT00242216 Comparator | May 2004 → Mar 2010 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT00386659 Background | — | HIV infectious disease | Hospital Clinic of Barcelona | Terminated | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT05721300 Background | Feb 2023 → Dec 2024 | chronic hepatitis B virus infection, hepatocellular carcinoma | Zhongshan Hospital (Xiamen), Fudan University | Unknown | No outcome recorded |
| — | NCT07618507 Comparator | Apr 2022 → Mar 2024 | HIV infectious disease | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT03988387 Background | Oct 2019 → Mar 2022 | HIV infectious disease | Columbia University | Completed | No outcome recorded |
| — | NCT03018821 Background | Jan → Oct 2017 | chronic hepatitis B virus infection | Xi'an Traditional Medicine Hospital | Unknown | No outcome recorded |
| — | NCT03251690 Comparator | Oct 2016 → Apr 2018 | HIV infectious disease, hyperlipidemia | Mahidol University | Completed | No outcome recorded |
| — | NCT01929759 Background | Jan 2014 → Oct 2015 | HIV infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01732224 Comparator | Nov 2012 → Apr 2014 | disease arising from reactivation of latent virus | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01614405 Comparator | Jun 2012 → Jul 2015 | primary biliary cholangitis | University of Alberta | Terminated | No outcome recorded |
| — | NCT01260610 Comparator | Jun 2011 | chronic hepatitis B virus infection | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| — | NCT01318096 Background | Mar 2011 → Jul 2012 | HIV infectious disease | Yunnan AIDS Care Center | Unknown | No outcome recorded |
| — | NCT00641641 Background | Mar 2008 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| — | NCT02454764 Comparator | ? → Jan 2018 | hepatitis B virus infection | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
Press releases naming this drug 186 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-12 | Gilead Sciences | Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial gilead.com ↗ |
| 2024-06-20 | Gilead Sciences | Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention gilead.com ↗ |
| 2024-03-28 | Gilead Sciences | FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six gilead.com ↗ |
| 2022-11-02 | Gilead Sciences | U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients gilead.com ↗ |
| 2020-10-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) Tablets in the U.S. tevapharm.com ↗ |
| 2020-08-11 | Gilead Sciences | China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP) gilead.com ↗ |
| 2019-11-06 | Gilead Sciences | Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® gilead.com ↗ |
| 2019-08-09 | Gilead Sciences | China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-07-23 | Gilead Sciences | Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada® gilead.com ↗ |
| 2019-05-09 | Gilead Sciences | Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic gilead.com ↗ |
| 2019-03-26 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women gilead.com ↗ |
| Show all 186 releases opens the full record — a long page | ||
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 356 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenofovir | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗272“DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗ “Tenofovir / emtricitabine + efavirenz for all HIV-1-infected men and all HIV-1-infected women who meet the following requirements: on effective contraception and no history of...” NCT00495651 ↗ “Patients will be on their existing nucleosid(t)e analogue therapy comprising lamivudine 100mg daily, adefovir 10mg daily, entecavir 0.5mg or 1.0mg daily or tenofovir 300mg...” NCT01928511 ↗ “one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir...” NCT01614405 ↗ “Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive patients infected by CCR5 HIV-1 previously treated for 6 months with a...” NCT01291459 ↗ “This study aims to investigate the clinical efficacy of Ganshuang granules combined with tenofovir, an antiviral drug, in the treatment of chronic hepatitis B complicated with...” PMID 36588741 ↗ Dec 2022 “women used a placebo or tenofovir (TFV) and levonorgestrel (LNG) intravaginal ring (IVR), either continuously or cyclically (three, 28-day cycles with a 3 day interruption in...” PMID 36215267 ↗ Oct 2022 “Otherwise, patients can be initiated on a preferred regimen of tenofovir (TDF), emtricitabine (FTC), and efavirenz (EFV) according to the US Department of Health and Human...” NCT00799136 ↗ “The purpose of this trial is to assess the safety and acceptability of Tenofovir (TFV) 1% gel in adolescent females over 12 weeks of a minimum of twice weekly dosing following...” NCT02245945 ↗ “Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA...” NCT06676410 ↗ “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “Tenofovir is a potent anti-human immunodeficiency virus (HIV) agent that decreased risk of herpes simplex virus type 2 (HSV-2) acquisition in HIV pre-exposure prophylaxis trials.” PMID 26044291 ↗ Jun 2015 “The investigators will investigate the effect of switching to Truvada (a combination pill of tenofovir and emtricitabine, the other two components of Atripla) plus raltegravir.” NCT01195467 ↗ “Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone” NCT02235662 ↗ “Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day” NCT01829802 ↗ “All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days” NCT01108926 ↗ “Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).” NCT01140880 ↗ “Influence of Female Reproductive Cycle and Menopause on Cervicovaginal Tissue Susceptibility to HIV-1 Infections and Tenofovir 1% Gel Activity” NCT01810315 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “Oral tenofovir is a key antiretroviral used for treatment and pre-exposure prophylaxis (PrEP) of human immunodeficiency virus (HIV).” PMID 41869811 ↗ Mar 2026 “randomized 2:2:1 to continuous use of a tenofovir/levonorgestrel (TFV/LNG), TFV, or placebo intravaginal ring (IVR).” PMID 37383290 ↗ Jun 2023 “delivery of tenofovir (TFV) gel among women at high risk of acquiring human immunodeficiency virus (HIV)” NCT02179138 ↗ “emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD” NCT00827112 ↗ “Patients will receive the Tenofovir/Lamiduvine NRTI drugs along with the Dolutegravir for 24 weeks.” NCT07618507 ↗ “Drug: * Tenofovir * Phyllanthus Urinaria * Adenosma Glutinosum * Eclipta Prostrata * Ascorbic Acid” NCT01198860 ↗ “Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)” NCT03602690 ↗ “TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension” NCT05850728 ↗ “with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC)” NCT04051970 ↗ “Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily” NCT01118871 ↗ “Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks” NCT01258439 ↗ “Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.” NCT03033836 ↗ “the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed” NCT00414635 ↗ “nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine” NCT03256422 ↗ “Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.” NCT01706575 ↗ “atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg” NCT01102972 ↗ “Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg” NCT01597934 ↗ “Name of Active Ingredients: Rilpivirine, tenofovir, emtricitabine” NCT02529059 ↗ “1. Tenofovir (including salt-free or salt-modifying drugs)” NCT05808335 ↗ “efavirenz 600 mg once daily plus tenofovir and lamivudine” PMID 24726095 ↗ Apr 2014 “Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg” NCT04734652 ↗ “tenofovir in addition to emtricitabine or lamivudine” NCT00662545 ↗ “Truvada is tenofovir 300 mg and emtricitabine 200 mg” NCT00762892 ↗ “Gammora® SC + Tenofovir/3TC + darunavir+ritonavir” NCT06799650 ↗ “Tenofovir 200mg/emtricitabine 300mg once a day” NCT01214759 ↗ “Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)” NCT06104306 ↗ “The NRTIs (including tenofovir/emtricitabine” NCT01516970 ↗ “Etecavir 0.5mg qd or Tenofovir 300mg qd” NCT05203055 ↗ “Emtricitabine + tenofovir + efavirenz” NCT01174914 ↗ “T101+ETV(Entecavir) /TDF(Tenofovir)” NCT04189276 ↗ “tenofovir/lamivudine/efavirenz” NCT02750059 ↗ “1. Tenofovir 245 mg once a day” NCT02588820 ↗ “tenofovir 245 mg daily” NCT01367236 ↗ “Tenofovir 300mg od” NCT02245022 ↗ “Tenofovir (300 mg)” NCT01605084 ↗ “Tenofovir (Viread)” NCT01373684 ↗ “tenofovir,” NCT02157311 ↗ “tenofovir” NCT01637259 ↗ |
| Known as | 3TC | “Clinical trials, including GEMINI, TANGO, SALSA, RUMBA, PASO DOBLE, and DYAD, have demonstrated that two-drug regimens, such as dolutegravir/lamivudine (DTG/3TC), offer...” NCT07138144 ↗ |
| Known as | 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate | “The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate),...” NCT01575405 ↗ |
| Known as | dual therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07138144 ↗ |
| Known as | Emtricitabine-tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01061151 ↗ |
| Known as | FTC/TDF | “one daily tablet of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) or one daily tablet of Truvada (emtricitabine 200 mg and tenofovir disoproxil...” NCT04742491 ↗2“Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.” NCT01380080 ↗ “FTC/TDF will be administered as open-label study drug in a fixed-dose combination formulation (Truvada).” NCT01338883 ↗ |
| Known as | PEG-IFN alfa-2a, Tenofovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00932971 ↗ |
| Known as | PMPA | “PMPA gel, also known as tenofovir, is an anti-microbe agent that may fight against sexual transmission of HIV and other sexually transmitted diseases (STDs).” NCT00028132 ↗2“containing 1% (w/w) of tenofovir (PMPA) formulated in purified water” NCT01575405 ↗ “containing 1% (w/w) of tenofovir (PMPA) formulated in purified water” NCT01575418 ↗ |
| Known as | TAF | “tenofovir (TDF ou TAF)” NCT03256422 ↗ |
| Known as | TDF | “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗54“BACKGROUND: The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable...” PMID 29329305 ↗ Jan 2018 “This randomized, three-period crossover, open-label, phase I trial assessed the effects of doravirine (DOR) and tenofovir disoproxil fumarate (TDF) on the pharmacokinetics...” PMID 38421210 ↗ Mar 2024 “All received a single 300-mg dose of oral tenofovir disoproxil fumarate (TDF) and were then randomized 2:1 to receive single and then seven daily rectal exposures of...” PMID 25350119 ↗ Oct 2014 “The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir...” NCT02097381 ↗ “the presence of low level nucleoside reverse-transcriptase inhibitor-resistant human immunodeficiency virus in subjects receiving failing first-line regimens consisting of...” PMID 19032103 ↗ Jan 2009 “Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in...” NCT01074645 ↗ “Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or...” PMID 25028911 ↗ May 2014 “A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the...” NCT02652260 ↗ “A phase 2 randomized, controlled trial of a regimen containing tenofovir (TDF)/lamivudine (3TC) and a regimen containing 3TC in HIV/HBV-coinfected pregnant women in China.” PMID 27658693 ↗ Sep 2016 “Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.” PMID 19542866 ↗ Jul 2009 “Arms A, B, and C receive the same daily dosage of lopinavir/ritonavir (LPV/r), emtricitabine (FTC), and stavudine extended release (d4T XR) or tenofovir DF (TDF).” NCT00036452 ↗ “we evaluated the antiviral efficacy and safety of entecavir (ETV) plus tenofovir (TDF) combination therapy in multidrug-resistant (MDR) CHB patients.” PMID 26781724 ↗ Feb 2016 “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “Switching to Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will result in faster and greater antiviral activity” NCT01597934 ↗ “The fixed-dose combination of Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV or Atripla®) is a highly effective HAART combination” NCT00936195 ↗ “Tenofovir plus emtricitabine/lamivudine (TDF/XTC)-based antiretroviral therapy (ART), which suppresses HIV and HBV replication” PMID 29020361 ↗ Jan 2018 “oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral placebo/tenofovir (TFV) vaginal gel, or double placebo” PMID 26044291 ↗ Jun 2015 “Treatment with PEG-IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression” PMID 37787009 ↗ Oct 2023 “providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with three adherence self-management interventions” PMID 36332953 ↗ Nov 2022 “This study aimed to explore the efficacy and safety of tenofovir (TDF) and telbivudine (LdT) in this population.” NCT02338674 ↗ “with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC)” NCT04051970 ↗ “emtricitabine 1 tablet (FTC) / tenofovir (TDF) (200/300 mg) once a day orally for 12 months” NCT01989611 ↗ “ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)” NCT00427297 ↗ “emtricitabine 1 tablet (FTC) / tenofovir (TDF) (200/300 mg) once a day orally for 12 months” NCT03220152 ↗ “tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC)” NCT01910402 ↗ “tenofovir disoproxil fumarate (TDF; 300 mg)-emtricitabine (FTC; 200 mg) tablets” PMID 18987623 ↗ Nov 2008 “common background of emtricitabine (FTC)/ tenofovir (TDF) 200/300 mg QD” NCT00757783 ↗ “Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI)” NCT03304717 ↗ “open label emtricitabine (FTC)/tenofovir (TDF) (Truvada®) as PrEP.” NCT01772823 ↗ “daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]” NCT03988387 ↗ “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC + DRV/r)” PMID 30365452 ↗ Dec 2018 “Arm 2: Tenofovir (TDF), emtricitabine (FTC), efavirenz (EFV)” NCT00127959 ↗ “tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy” PMID 25800784 ↗ Mar 2015 “tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy” PMID 25596179 ↗ Jan 2015 “Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)” NCT00759070 ↗ “tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)” NCT00335322 ↗ “tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg qd” PMID 22592092 ↗ May 2012 “Tenofovir disoproxil fumarate (TDF) 300 mg tablets” NCT02116660 ↗ “which are TDF (Tenofovir) and FTC (Emtricitabine)” NCT03251690 ↗ “tenofovir (TDF) 300mg + emtricitabine (FTC) 200mg” NCT00192634 ↗ “Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV)” NCT04022967 ↗ “Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)” NCT02632474 ↗ “Tenofovir (TDF) 300 mg po once a day (OD)” NCT03759782 ↗ “Atazanavir(ATZ) and Tenofovir(TDF)” NCT01368783 ↗ “emtricitabine-tenofovir(FTC/TDF)” NCT02770508 ↗ “tenofovir (TDF ou TAF)” NCT03256422 ↗ “Tenofovir (TDF) 300 mg” NCT06676410 ↗ “Tenofovir (TDF)” NCT02386098 ↗ “Tenofovir (TDF)” NCT00158457 ↗ “tenofovir (TDF)” NCT00799136 ↗ “TDF (Tenofovir)” NCT02404259 ↗ “Tenofovir (TDF)” NCT01232127 ↗ |
| Known as | TDF/FTC | “HIV-infected participants will receive Truvada (TDF/FTC) and EFV for the first 30 days.” NCT01040091 ↗ |
| Known as | Tenofovir 300mg - Viread | “Tenofovir 300mg - Viread” NCT01594905 ↗ |
| Known as | Tenofovir = Viread | “Tenofovir = Viread” NCT00441298 ↗ |
| Known as | tenofovir df | “Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.” PMID 19542866 ↗ Jul 20093“Arms A, B, and C receive the same daily dosage of lopinavir/ritonavir (LPV/r), emtricitabine (FTC), and stavudine extended release (d4T XR) or tenofovir DF (TDF).” NCT00036452 ↗ “300mg tenofovir df + 200 mg emtricitabine by mouth daily” NCT00414635 ↗ “* tenofovir DF 300 mg” NCT00474435 ↗ |
| Known as | Tenofovir DF/Emtricitabine | “The objective of the proposed demonstration project with Tenofovir DF/Emtricitabine (TDF/FTC) among Female Sex Workers (FSW) in Dakar Senegal is to build a sustainable HIV PrEP...” NCT02474303 ↗ |
| Known as | tenofovir disoproxil | “tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg” NCT03546621 ↗ |
| Known as | tenofovir disoproxil fumarate | “BACKGROUND: The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable...” PMID 29329305 ↗ Jan 201816“Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in...” NCT01074645 ↗ “A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the...” NCT02652260 ↗ “ritonavir-boosted darunavir with either raltegravir or tenofovir disoproxil fumarate and emtricitabine in antiretroviral therapy (ART)-naive adults.” PMID 33794182 ↗ Apr 2021 “All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)” NCT00984971 ↗ “Switching to Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will result in faster and greater antiviral activity” NCT01597934 ↗ “oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral placebo/tenofovir (TFV) vaginal gel, or double placebo” PMID 26044291 ↗ Jun 2015 “Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence.” PMID 31430318 ↗ Aug 2019 “Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will show effective antiviral activity” NCT01594905 ↗ “emtricitabine with tenofovir disoproxil fumarate (FTC/TDF, 200/300 mg given orally for 10 days)” PMID 34957385 ↗ Dec 2021 “tenofovir disoproxil fumarate (TDF; 300 mg)-emtricitabine (FTC; 200 mg) tablets” PMID 18987623 ↗ Nov 2008 “tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg” NCT03546621 ↗ “Tenofovir disoproxil fumarate was supplied in 300 mg tablets” NCT00805675 ↗ “tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy” PMID 25800784 ↗ Mar 2015 “tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy” PMID 25596179 ↗ Jan 2015 “Viread (300 mg Tenofovir disoproxil fumarate) once daily” NCT00356616 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg tablets” NCT02116660 ↗ |
| Known as | Tenofovir disoproxilfumarat | “Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally” NCT00932971 ↗ |
| Known as | Tenofovir Film | “Drug: Tenofovir Film” NCT02280109 ↗ |
| Known as | Tenofovir Gel | “Drug: Tenofovir Gel” NCT02280109 ↗ |
| Known as | tenofovir td | “300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine” NCT00414635 ↗ |
| Known as | Tenofovir/Emtricitabine | “100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.” NCT00242216 ↗1“pregnant AGYW (age: 16-25 years) who initiated daily oral PrEP (Tenofovir/Emtricitabine) antenatally” PMID 36947792 ↗ Mar 2023 |
| Known as | TFV | “All received a single 300-mg dose of oral tenofovir disoproxil fumarate (TDF) and were then randomized 2:1 to receive single and then seven daily rectal exposures of...” PMID 25350119 ↗ Oct 201423“The concordance of quantifiable FTC-TP in DBS with tenofovir (TFV)/FTC in plasma was evaluated by utilizing paired plasma-DBS samples from participants enrolled in 2 large...” PMID 27572401 ↗ Oct 2016 “women used a placebo or tenofovir (TFV) and levonorgestrel (LNG) intravaginal ring (IVR), either continuously or cyclically (three, 28-day cycles with a 3 day interruption in...” PMID 36215267 ↗ Oct 2022 “This was followed by the final phase of the study (Stage 2) in which a subset of participants from Stage 1B were enrolled into a Phase 1 rectal safety and acceptability...” PMID 27362788 ↗ Jun 2016 “In this Phase 1 vaginal film study, the safety, acceptability, pharmacokinetics and pharmacodynamics of two doses of tenofovir (TFV) film and TFV 1% gel were compared to...” PMID 30101439 ↗ Aug 2018 “The purpose of this trial is to assess the safety and acceptability of Tenofovir (TFV) 1% gel in adolescent females over 12 weeks of a minimum of twice weekly dosing following...” NCT02245945 ↗ “Our team developed an intravaginal ring (IVR) that delivers tenofovir (TFV) (8-10 mg/day) alone or with levonorgestrel (LNG) (20 ug/day).” PMID 31107913 ↗ May 2019 “oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral placebo/tenofovir (TFV) vaginal gel, or double placebo” PMID 26044291 ↗ Jun 2015 “systemic exposure to tenofovir (TFV) 1% gel and a given commonly used vaginal product are impacted by concomitant use” NCT01813162 ↗ “Tenofovir (TFV) gel partially protected against human immunodeficiency virus (HIV) in one but not subsequent trials.” PMID 26508513 ↗ Oct 2015 “randomized 2:2:1 to continuous use of a tenofovir/levonorgestrel (TFV/LNG), TFV, or placebo intravaginal ring (IVR).” PMID 37383290 ↗ Jun 2023 “Tenofovir (TFV) 1% vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus.” PMID 21930612 ↗ Sep 2011 “delivery of tenofovir (TFV) gel among women at high risk of acquiring human immunodeficiency virus (HIV)” NCT02179138 ↗ “Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens.” PMID 22039430 ↗ Oct 2011 “Purpose of the study is to assess tenofovir (TFV) PK and PD endpoints” NCT01810315 ↗ “an investigational intravaginal ring containing tenofovir (TFV)” NCT02722343 ↗ “a 90-day intravaginal ring (IVR) containing tenofovir (TFV)” NCT03670355 ↗ “three tenofovir (TFV) gels for rectal application” PMID 25942472 ↗ May 2015 “a one-dose tenofovir (TFV) medicated douche” NCT04686279 ↗ “Tenofovir (TFV) Alone Vaginal Tablet” NCT01694407 ↗ “tenofovir (TFV) drug concentrations” NCT03719053 ↗ “tenofovir (TFV) enema” NCT02750540 ↗ |
| Known as | TFV RG | “tenofovir reduced-glycerin (TFV RG) 1% gel” NCT01768962 ↗ |
| Known as | Truvada | “For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to...” NCT05072093 ↗45“one daily tablet of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) or one daily tablet of Truvada (emtricitabine 200 mg and tenofovir disoproxil...” NCT04742491 ↗ “Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir” NCT02336074 ↗ “Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.” NCT02577042 ↗ “tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV” NCT00708162 ↗ “bulk pills (Truvada and Zinnia F) for encapsulation” NCT04778527 ↗ “Truvada” NCT00737724 ↗ |
| Known as | Truvada [TRV] | “Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail” NCT01061151 ↗ |
| Known as | TRV | “Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail” NCT01061151 ↗ |
| Known as | Viread | “All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)” NCT00984971 ↗2“Tenofovir, with potent activity against retroviruses \[1\], was developed for oral use as Viread®, which is widely used for HIV treatment.” NCT01387022 ↗ “Viread (300 mg Tenofovir disoproxil fumarate) once daily” NCT00356616 ↗ |
| Known as | Zinnia F | “bulk pills (Truvada and Zinnia F) for encapsulation” NCT04778527 ↗ |
| Action | Inhibit | “existing dual nucleoside analogue reverse transcriptase inhibitor therapy to coformulated tenofovir-emtricitabine or abacavir-lamivudine” PMID 24722774 ↗ Apr 2014 |
| Modality | Small molecule | “an acyclic nucleoside phosphonate, tenofovir (TDF)” NCT00214890 ↗ |
| Route | Oral | “Active Comparator, Capsules, tablets, Oral” NCT00035932 ↗ |